
Suraksha Diagnostic Limited - IPO
MAINBOARDSuraksha Diagnostic Stock Price


Suraksha Diagnostic IPO Details
Suraksha Diagnostic IPO Subscription
Suraksha Diagnostic IPO Application Wise Breakup (Approx)
Suraksha Diagnostic IPO Dates
- 29 Nov 2024Opening dateOPD
- 03 Dec 2024Closing dateCOD
- 04 Dec 2024Basis of AllotmentBOA
- 05 Dec 2024Initiation of RefundsIOR
- 05 Dec 2024Credit of SharesCOS
- 06 Dec 2024Listing dateLID
Suraksha Diagnostic IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retain Minimum | 1 | 34 | ₹14,994 |
Retain Maximum | 13 | 442 | ₹194,922 |
SHNI Minimum | 14 | 476 | ₹209,916 |
SHNI Maximum | 66 | 2244 | ₹989,604 |
BHNI Minimum | 67 | 2278 | ₹1,004,598 |
Suraksha Diagnostic IPO Reservation
Promoter Holding
Suraksha Diagnostic IPO Valuations
Suraksha Diagnostic Limited Financial Information
Suraksha Diagnostic Limited's revenue increased by 14.75% and profit after tax (PAT) rose by 281.32% between the financial year ending with March 31, 2024 and March 31, 2023.
Period Ended | 30 Jun 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 314.20 | 300.21 | 281.20 | 275.96 |
Revenue | 61.85 | 222.26 | 193.69 | 225.77 |
Profit After Tax | 7.67 | 23.13 | 6.07 | 20.82 |
Net Worth | 187.05 | 179.41 | 155.93 | 145.84 |
Reserves and Surplus | 176.80 | 170.88 | 147.40 | 137.31 |
Total Borrowing | 7.57 | 8.64 | 14.01 | 19.03 |
Amount in ₹ Crore |
About Suraksha Diagnostic IPO
Incorporated in 2005, Suraksha Diagnostic Limited offers pathology, radiology testing and medical consultancy services. The company has a central reference laboratory with 8 satellite laboratories and 215 customer touchpoints, including 49 diagnostic centres and 166 sample collection centres as of June 30, 2024, across West Bengal, Bihar, Assam, and Meghalaya.
The company offers its customers online and offline medical consultation services under one roof via 44 diagnostic centres, which house 120 polyclinics with more than 750 doctors.
The operation of the diagnostic centres is supported by the technology platforms and systems that the company uses to streamline, such as its Laboratory Information Management System ("LIMS"), its fully integrated Radiology Information System ("RIS"), its Picture Archive Communication System ("PACS") and its Enterprise Resource Planning System ("ERP").
The company offers vaccination services and customized testing packages for disease prediction/early detection. The company uses digital pathology and artificial intelligence to generate blood tests. All radiology reporting is done through a digital platform that allows cases to be reported from all diagnostic centres, significantly reducing turnaround time.
Competitive Strengths are:
- Well-positioned diagnostics chain to capture the large growth opportunities for organized diagnostics chains in the fragmented markets for diagnostic services in eastern and northeastern India.
- Integrated diagnostics provider offering pathology and radiology testing and medical consultancy services from a single source.
- Well-invested and technologically advanced clinical infrastructure.
- Commitment to quality driving high individual consumer business share and customer retention.
- Management team with relevant industry experience.
Strength Of Suraksha Diagnostic IPO
1. Diagnostic chain with in eastern India well positioned to leverage growth opportunity for organized diagnostic chains in the diagnostic services markets in eastern and north-eastern India.
2. Track record of profitability and financial performance.
3. Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.
4. Technologically advanced clinical infrastructure and trained personnel providing diagnostic services.
5. Commitment to quality driving high individual consumer business share and customer retention.
6. Management team with relevant industry experience.
Risk Of Suraksha Diagnostic IPO
1. 95.48% of its Revenue from Operations in Fiscal 2024 was generated from West Bengal, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.
2. The securities of certain of its Promoter Group members have been suspended from trading on a recognized stock exchange in the past. The company cannot assure you that there will be no such instances in the future which may adversely affect its operations, reputation and ability to raise capital through further public issue of securities.
3. The diagnostics industry in India is highly competitive and its inability to compete effectively from other healthcare service providers may adversely affect its business, results of operations and financial condition. Further, as of Financial Year 2024, the market share of the Company in its major market which is East India is 1.15-1.30%.
4. The B2B segment contributed to 6.17% of its Revenue from Operations in Fiscal 2024 and any non-renewal or cancellation of its arrangements with its institutional customers, including hospitals, and Public-Private Partnership ("PPP") contracts may adversely affect its business, results of operations and financial condition.
5. Its Statutory Auditors have included certain emphasis of matters, and audit qualifications matters prescribed in the audit reports of the Company for Fiscals 2023 and 2024.
6. In the past, the company failed to comply with certain provisions of the Companies Act, 2013, and had to compound such non-compliances. The company cannot assure you that there will be no such non-compliances in the future and that the Company, Promoters, or Directors will not be subject to any penalty or additional payment.
7. Certain of its Promoters, Directors, Subsidiaries and Group Company are in businesses similar to its and have interests in certain companies, which are in similar businesses to its, and this may result in potential conflict of interest with the company.
8. Its Promoters and certain members of the company Promoter Group pledged some of the Equity Shares held by them in favour of Vistra ITCL (India) Limited, in its capacity as debenture trustee for the benefit of the debentureholders, as security for debentures issued by its Promoter Group entity, Tinni Investments Limited, and there are disposal restrictions created on Equity Shares held by certain other shareholders. Upon creation, any invocation of such pledge could dilute the aggregate shareholding of its Promoters, and such members of the company Promoter Group, which may cause a change in control of the Company and trigger an open offer requirement under the Takeover Regulations.
9. There are outstanding legal proceedings involving the Company, Subsidiaries, Promoters, Directors and Group Companies which may adversely affect its business, financial condition and results of operations.
10. The Company will not receive any proceeds from the Offer for Sale. The Selling Shareholders will receive the entire net proceeds from the Offer for Sale.
Objectives Suraksha Diagnostic IPO
The Company will not receive any proceeds from the Offer for sale and all proceeds will go to the Selling Shareholders.
Company Contact Details
Suraksha Diagnostic Limited
Plot No. DG-12/1
Action Area 1D, Premises No. 02-0327
New Town, Rajarhat Kolkata 700 156
Phone: 91 33 66059750
Email: investors@surakshanet.com
Website: https://www.surakshanet.com/
Registrar Contact Details
Lead Mangers
ICICI Securities Limited
SBI Capital Markets Limited
Nuvama Wealth Management Limited